EFS and in situ carcinoma: Apoptosis markers of cleaved caspase 3 (CAS3), together with the caspase-cleaved and formalin-resistant cytokeratin 18 neo-epitope (M30), were increased in the DZ-CIS treated group compared to CIS-treated group (Fig. 6A).